The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …

The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …

Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …

Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

The main protease (Mpro) is a validated antiviral drug target of SARS-CoV-2. A number of
Mpro inhibitors have now advanced to animal model study and human clinical trials …

The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …

Since the outbreak of COVID-19, caused by the SARS-CoV-2, in December 2019, the
ongoing pandemic has posed 5 318 216 deaths worldwide. 1 Vaccines, traditional Chinese …

The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
has resulted in a long pandemic, with numerous cases and victims worldwide and enormous …